Related Experiment Video
Updated: Jul 16, 2026
10:46
Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
Published on: May 3, 2017
Animal models for glutaryl-CoA dehydrogenase deficiency
D M Koeller1, S Sauer, M Wajner
1Department of Pediatrics, Oregon Health and Science University, Portland, Oregon 97239, USA. koellerd@ohsu.edu
Journal of Inherited Metabolic Disease
|October 27, 2004
Summary
Glutaryl-CoA dehydrogenase (GCDH) deficiency causes striatal damage via excitotoxicity. Animal models show this mechanism is complex, with cerebral enzyme activity potentially protecting against neurological symptoms.
Area of Science:
- Biochemistry
- Neuroscience
- Genetics
Background:
- Glutaryl-CoA dehydrogenase (GCDH) deficiency is linked to excitotoxic striatal damage.
- Accumulating organic acids, 3-hydroxyglutaric acid (3-OH-GA) and glutaric acid (GA), are implicated in neurotransmitter imbalance.
Purpose of the Study:
- To investigate the in vivo pathophysiology of GCDH deficiency.
- To understand the role of cerebral GCDH activity in neuroprotection.
Main Methods:
- Generated a GCDH-deficient mouse model.
- Utilized the fruit-eating bat (Rousettus aegypticus) as a natural animal model.
- Administered 3-OH-GA and GA stereotaxically in rats (prior studies).
Main Results:
- GCDH-deficient mice exhibit the biochemical phenotype and spongiform myelinopathy but lack acute striatal damage.
- Bats show the biochemical phenotype but no overt neurological symptoms, despite retaining cerebral GCDH activity.
- Rodent models suggest species differences may influence striatal vulnerability.
Conclusions:
- Cerebral GCDH activity might protect against neuronal damage in GCDH deficiency.
- The lack of striatal damage in models highlights unknown factors modulating neurosusceptibility.
- Further research is needed to understand GCDH deficiency pathophysiology and develop neuroprotective strategies.
